The purpose of this study is to examine the effects of resistance exercise, such as weightlifting, on retention of muscle mass and mental health in individuals taking GLP-1 RAs (an obesity medication). Resistance exercise is focused on increasing the strength of participants' muscles, such as how much participant can lift.
•The duration of this study is 3 months. This includes:
* Orientation session to explain study protocol, exercise program, and complete questionnaire about participants' medical history and lifestyle.
* Two health assessments at baseline and at 3 months. These assessments include body composition, resting blood pressure, cardiovascular function, and muscular strength. Both the resistance exercise group and the control group will complete assessments at baseline and again at 3 months. After the 3-month period, individuals in the control group may choose to participate in the exercise training and complete the optional 6-month assessments.
* Personalized resistance exercise sessions for 60 minutes per session, twice per week, for 3 months.

Start Date25 May 2026

Sponsor / Collaborator

University of Pittsburgh

[+1]

ChiCTR2600123454

/ Not yet recruitingNot ApplicableIIT

Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study

Start Date01 May 2026

Sponsor / Collaborator

Wannan Medical College

NCT07537088

/ Not yet recruitingPhase 4IIT

Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study

The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of Sodium-Glucose Co-Transporter 2 Inhibitors(SGLT2i) and finerenone can provide additional kidney protection and safety for Chinese adults with Type 2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease(CKD). Eligible participants will be adults with T2DM and mild-to-moderate CKD who have been receiving SGLT2 inhibitor plus finerenone for at least 3 months on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi). Participants will be randomly assigned to either continue the original regimen or to receive add-on therapy with dulaglutide.The study will last for 26 weeks, with participants required to attend scheduled visits for efficacy and safety assessments at Week 13 (±1 week) and Week 26 (±1 week, final visit).

Start Date01 May 2026

Sponsor / Collaborator

Wannan Medical College

100 Clinical Results associated with Dulaglutide

100 Translational Medicine associated with Dulaglutide

100 Patents (Medical) associated with Dulaglutide

1,620

Literatures (Medical) associated with Dulaglutide

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Calculating cost per event avoided using a composite number needed to treat

Article

Author: Wang, Julia ; Bhavsar, Jigish ; Toliver, Joshua ; Sullivan, Sean D.

OBJECTIVE:

Number needed to treat (NNT) and cost per event avoided (CPEA) are measures used to represent the clinical and economic value of chronic treatments and are commonly calculated based on primary endpoints from trials. This approach, although widely used, does not reflect the complete value of a treatment, as it does not consider outcomes beyond the primary endpoints. This research aims to overcome this limitation by developing multiple composite NNTs to derive the CPEA to estimate a total value of semaglutide and dulaglutide in people with established cardiovascular disease.

METHODS:

Two cardiovascular outcomes trials were selected, SELECT (NCT03574597, semaglutide 2.4 mg) and REWIND (NCT01394952, dulaglutide 1.5 mg). NNT was calculated as NNT = 1/ARR where ARR = control event rate - experimental event rate. NNT was estimated for 3-point major adverse cardiovascular events (MACE-3; primary endpoint of the trials), 5-point MACE (MACE-5), and cardiovascular-kidney-metabolic events (CKM). CPEA of MACE-3, MACE-5, and CKM was calculated as NNT*duration of mean follow-up (semaglutide) or duration of median follow-up (dulaglutide)*estimated net price.

RESULTS:

The NNT decreased as the number of outcomes in the composite endpoint increased, where NNT_MACE-3, NNT_MACE-5, and NNT_CKM were 67, 49, and 8 for semaglutide, and 72, 64, and 23 for dulaglutide, respectively. Similarly, the CPEA decreased as the number of outcomes in the composite endpoint increased, where the CPEA for MACE-3, MACE-5 and CKM calculations were $1,662,001, $1,232,417, and $190,387 for semaglutide and $1,884,013, $1,670,366, and $607,886 for dulaglutide.

CONCLUSIONS:

This research illustrates the limitations of using a NNT focused only on the primary endpoint, as it does not capture the total benefit of the treatment. When considering the value of treatments through NNT or CPEA analyses, a composite endpoint capturing broader benefit should be utilized.

31 Dec 2026·ANNALS OF MEDICINE

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers

Review

Author: Chikatimalla, Rahul ; Aggarwal, Kanishk ; Shah, Twinkle ; Perry, Griffin ; Shah, Ashka ; Banker, Himanshi ; Jain, Rohit

OBJECTIVES:

To evaluate the current evidence supporting the cerebrovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM), and to outline their mechanisms of action in stroke prevention.

METHODS:

A narrative review was conducted by synthesising data from cardiovascular outcome trials, meta-analyses and mechanistic studies involving GLP-1RAs such as semaglutide, liraglutide and dulaglutide. The search included literature on ischaemic stroke incidence, molecular pathways and clinical outcomes associated with GLP-1RA therapy.

RESULTS:

GLP-1RAs exhibit multiple protective mechanisms, including anti-inflammatory, antioxidant, neuroprotective and endothelial-stabilising effects. Long-acting agents demonstrate superior efficacy in reducing nonfatal and ischaemic stroke risk, with relative risk reductions ranging from 15% to 39% across major trials. These benefits are observed independent of glycemic control and appear most prominent in patients with preserved renal function and shorter diabetes duration. In contrast, short-acting exendin-based GLP-1RAs show limited cerebrovascular benefit. Treatment response may vary based on factors such as stroke subtype, baseline vascular risk and comorbidities.

CONCLUSION:

GLP-1RAs offer significant promise as adjunctive pharmacotherapy for stroke prevention in individuals with T2DM. Their multifactorial benefits extend beyond glucose regulation and may influence clinical outcomes through systemic vascular and neuroprotective mechanisms. However, inconsistencies in trial outcomes and limited data in non-diabetic or high-risk populations underscore the need for targeted stroke-specific studies. Personalised treatment approaches and broader risk stratification may optimise their use in cerebrovascular disease management.

01 Sep 2026·Case reports in women's health

Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series

Article

Author: Wong, Karen ; Al-Amri, Houda ; Werlang, Ana

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has increased over the past several years. The resulting improved blood sugar control and optimized body weight ultimately improve fertility. Thus, it is increasingly common to have individuals inadvertently becoming pregnant while using GLP-1 RAs. This case series describes outcomes following the inadvertent use of GLP-1 RAs in the first trimester of pregnancy, including the incidence of major malformations, maternal glucose control and gestational weight gain. This case series included individuals receiving obstetric care at a tertiary perinatal center who had exposure to a GLP-1 RA between 2 months preconception to pregnancy conclusion for any indication or duration. Electronic medical records of participants were reviewed for fetal, obstetrical, maternal, and neonatal outcomes. There were 16 patients in the series. All had spontaneous and unplanned conception of singleton pregnancies while using subcutaneous semaglutide and continued administration during a part of the first trimester. All included patients were overweight or obese. No individual lost weight in pregnancy. No major fetal anomalies were identified. Following discontinuation of semaglutide, diabetes control required both metformin and insulin for most patients. There was one instance of iatrogenic preterm birth at 35 weeks for preeclampsia. The rate of preeclampsia was 18.8%. Given the high rate of obesity, there was a lower-than-expected rate of excessive gestational weight gain (37.5%). Further studies on the safety and possible benefits of GLP-1 RAs in pregnancy are required.

542

News (Medical) associated with Dulaglutide

28 Jul 2026

·www.genohopebio.com

New Study Finds Compounded GLP-1s Remain Robust Despite End Of Shortages

Jul 28, 2026 View: 104 Leave a message Secret-shopper calls to 75 sites found 92.0% offering compounded semaglutide, 86.7% compounded tirzepatide, and 9.3% oral/sublingual formulations, indicating persistent postshortage market penetration. Additive-containing formulations were common (58.7%), most often B vitamins (56.0%), plus levocarnitine and glycine, reflecting a shift toward product differentiation without established clinical benefit. Nonphysician clinicians frequently conducted consultations (56.0%), with variable follow-up requirements, raising concerns about consistency of monitoring and adverse-event surveillance in commercialized settings. Identified suppliers included facilities with sterile compounding licensing gaps (19.0%), FDA warning letters, and state disciplinary actions, underscoring quality risks alongside counterfeit and impurity allegations. FDA proposals to exclude key GLP-1s from the 503B bulk list and warning letters targeting "identical" marketing claims increase compliance pressure, particularly for scaled distribution resembling manufacturing. A secret shopper study finds most are still compounding semaglutide and tirzepatide with additives, often through suppliers lacking sterile compounding licenses. A new cross-sectional study published in JAMA Health Forum found that compounded glucagon-like peptide-1 receptor agonist (GLP-1 RA) products remain widely available at brick-and-mortar weight loss clinics and medical spas, even after the FDA declared the semaglutide and tirzepatide shortages resolved. Researchers from the University of Colorado Anschutz Medical Campus conducted secret shopper calls to 75 businesses in West Virginia and Oklahoma between August and October 2025, finding that most were still offering compounded products, frequently combined with additives whose clinical benefit remains unproven.1 Of the 75 businesses confirmed to offer compounded GLP-1 RAs, 69 (92.0%) reported offering compounded semaglutide and 65 (86.7%) reported offering compounded tirzepatide. Seven businesses (9.3%) offered oral or sublingual formulations. Additives were common, with 44 of 75 businesses (58.7%) confirming their products were compounded with an additive, most often B vitamins (42 businesses, 56.0%), followed by levocarnitine (5 businesses, 6.7%) and glycine (4 businesses, 5.3%).1 Most consultations were conducted by nurse practitioners or physician assistants (42 of 75 businesses, 56.0%), rather than physicians (30 businesses, 40.0%). Most businesses (52 of 75, 69.3%) required in-person consultations, and 46 of 75 (61.3%) required follow-up appointments at least once monthly, though 17 businesses (22.7%) required less-frequent follow-up or none at all.1 Researchers also identified 24 compounding pharmacy suppliers behind these products, located across at least 6 states. Among 21 facilities for which sterile compounding license status could be confirmed, 4 (19.0%) were not licensed to perform sterile compounding. One facility had received 2 FDA warning letters since 2023, both citing sterile compounding violations, and 3 of 22 facilities (13.6%) had faced state board of pharmacy disciplinary action. The study authors concluded that the FDA's decision to resume enforcement against copycat compounding appears to have pushed the market toward additive-based products rather than eliminating it.1 The study's findings land alongside a broader FDA effort to tighten the regulatory window for GLP-1 compounding. The agency has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk list, the list of active pharmaceutical ingredients that FDA-registered outsourcing facilities may use to compound in bulk. The proposal would not directly affect 503A pharmacies, which compound to individual patient prescriptions under state board oversight rather than the bulk list, though 503B facilities may still compound these drugs during a declared shortage.2 The regulatory tightening follows a wave of FDA warning letters to 30 telehealth companies over marketing claims that compounded GLP-1s are "identical" to approved products and litigation from Novo Nordisk alleging that some compounded semaglutide contained impurities as high as 86%.2,3 Separately, a National Pharmacy Association survey covering 6000 British pharmacies found that roughly 1 in 10 online pharmacies had their websites or social media accounts cloned by criminals seeking to sell counterfeit weight-loss medications. Two in 5 pharmacies reported encountering patients who had unwittingly purchased treatments from unregulated sources. In some cases, counterfeiters stole legitimate pharmacist videos or copied regulator logos to appear credible. One pharmacy reported a patient who discovered they had been defrauded only after a counterfeit tirzepatide pen produced no health benefit.3 "The lesson is simple and has been consistent, which is 503A pharmacies must remain patient-specific in both form and reality," Dae Lee, PharmD, Esq, CPBS, shareholder at Buchanan Ingersoll & Rooney, said.3 "High-volume, standardized formulation, and national distribution are no longer being treated as aggressive compounding. They're being treated as manufacturing. If your GLP-1 business model depends on the scale rather than individualized prescriptions, you might be exposed." For pharmacists navigating this landscape, the compliance stakes are rising alongside enforcement. Annie Lambert, PharmD, BCSCP, clinical program manager for compliance solutions at Wolters Kluwer, said community pharmacists compounding GLP-1s need to be able to justify their anticipatory batch sizes.4 "For community pharmacists that are performing GLP-1 compounding, they really need to be prepared to justify their rationale for their anticipatory batch quantities to avoid the impression of mass production," Lambert said.4 "I think that's where the FDA is really targeting in on some of their quantities." Lambert noted that pharmacies not directly involved in compounding still play a role, since patients often bring questions about sourcing and legitimacy directly to the counter. She recommended that pharmacies emphasize accreditation, such as Pharmacy Compounding Accreditation Board certification or National Association of Boards of Pharmacy Verified Pharmacy Program status, and be transparent that 503A compounding requires a prescription rather than a menu of selectable products.4 Taken together, the new study and the surrounding regulatory activity suggest that even as the FDA narrows the legal pathways for large-scale GLP-1 compounding, patient demand-and the risks that come with meeting it outside FDA-approved channels-show little sign of receding. GenoHope Biotech Ltd. A leading manufacturer of GLP-1 API Approal by FDA Welcome any Inquiry WhatsApp/Tel:+8613833133635 Email:info@genohopebio.com Send Inquiry

22 Jul 2026

·www.businesswire.com

Atropos Health Has 12 New Peer-Reviewed Research Studies Across Numerous Disease States Published in First Half of 2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the world’s largest creator of real-world evidence (RWE) for clinical decision making, today announced that it has contributed to 12 new studies in the first six months of 2026, powered by high-quality real-world data from the Atropos Evidence™ Network and Atropos Health’s AI-driven real world evidence tools. This new collection of research and conference presentations spans multiple disease states and demonstrates how real-world evidence accelerates clinically meaningful insights. A selection of these publications are summarized below and were presented at major conferences including ASCO 2026, the Society for Investigative Dermatology, the American Society of Clinical Psychopharmacology, ISPOR and Digestive Disease Week. Association between Semaglutide and Risk of Bone Fractures in Type 2 Diabetes - presented at ENDO2026 evaluated fracture incidence and body mass index (BMI) changes among type 2 diabetes patients treated with semaglutide versus dulaglutide or alternative weight loss drugs (phentermine/topiramate, bupropion/naltrexone). Overall, researchers found the semaglutide treatment was associated with a greater BMI reduction and 15% reduction in fracture incidence. Antidepressant Use and Melanoma Immunotherapy: An Unexpected Signal – presented at ASCO 2026 to examine whether SSRIs influence outcomes in patients with metastatic melanoma who receive immune checkpoint inhibitor therapy. mRNA vs. DNA COVID-19 Vaccines and Autoimmune Risk: Nuanced Findings from a Large Cohort – presented at the SID Annual Meeting 2026, the study found that there is a trend towards higher autoimmune risk after mRNA vaccination and should require additional research. Statins May Protect Against Intestinal Strictures in Crohn’s Disease – published in the Journal of Crohn’s and Colitis in March 2026, this study evaluated two national databases about how drug repurposing discovery, powered by real-world evidence can show secondary benefits. Alcohol Use Disorder: A Persistent Gap in Hospital Care – published in Alcohol and Alcoholism, the study showed that fewer than 3% of hospitalized patients with alcohol use disorder received any medication-assisted treatment. Machine Learning Targets Bipolar Disorder and Schizophrenia Treatment Selection – presented at ASCP Annual Meeting 2026. These two posters demonstrated how machine learning and real-world data can help identify which patients with bipolar 1 and schizophrenia could most likely benefit from the long-acting injectable, aripiprazole monohydrate. These insights will continue to grow as Alexandria®, the Atropos Evidence™ Library, which was already the largest source of novel medical content - with over 33M precision Evidence-Based Findings, is expected to grow to two billion pEBFs by the end of 2026. This increased scale will exceed all known medical evidence by 100x in volume. “By utilizing our high-throughput evidence-creation tools, we are delivering robust, peer-reviewed real-world evidence at a scale and speed previously unimaginable,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “These 12 new studies across diverse disease states demonstrate that we are doing more than generating data. We are filling the evidence gap with actionable, trusted insights that empower the entire healthcare ecosystem to make the best possible care decisions today. Atropos Health is fundamentally changing how care teams make daily medical decisions that are backed by high-quality evidence.” This library is enabling the entire healthcare ecosystem - clinicians, researchers, life science partners, and others - to generate precise answers to complex medical questions quickly and improve patient and medical outcomes based on content not available anywhere else. About Atropos Health Atropos Health is closing medicine's most consequential gap: actionable evidence to inform the vast majority of clinical decisions that are made without evidence. By generating real-world evidence from actual patient outcomes and data, Atropos Health is building the evidence infrastructure that clinicians, life science researchers and AI platforms need to practice, develop and inform medicine, grounded in what actually works. Better healthcare is only possible with evidence, and Atropos Health is working to make it available for every patient, in every healthcare decision, every day. Atropos Health does this via GENEVA OS®, the operating system across a robust network of real-world data; Alexandria, the world’s largest evidence library; and evidence generation tools such as ChatRWD®, Green Button® and the Atropos Evidence™ Agent. To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or X (Twitter).

Clinical StudyImmunotherapyASCO

23 Jun 2026

·www.biospace.com

Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults

U.S. Phase 2 trial met primary endpoints, with up to 11.5% weight loss at 36 weeks, showing continued weight reduction at a consistent rate and no evidence of a slowing trajectory CX11 demonstrated favorable GI tolerability and safety profile, with a markedly low vomiting rate, ranging from 12-16% No hepatic safety signal observed in the U.S. P2 and China P3 studies BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals Limited (“CORXEL”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients living with cardiometabolic conditions around the world, today announced positive top-line results from its Phase 2 trial evaluating CX11, an oral small molecule GLP-1 receptor agonist (GLP-1 RA), in obese and overweight participants in the United States. Building on these results and the successful China obesity Phase 3 results recently announced by its partner Vincentage Pharma Co., Ltd., CORXEL plans to advance into pivotal global Phase 3 studies of CX11 in weight management. The Phase 2 trial (NCT07011797) enrolled 246 adults with obesity (BMI ≥30 kg/m²) or who were overweight (27 kg/m² ≤ BMI <30 kg/m²) with at least one weight-related comorbidity in the United States. Participants were randomized 1:1:1:1:1 to receive CX11 120 mg, CX11 160 mg, CX11 200 mg (slow titration), CX11 200 mg (fast titration) or placebo once daily for 36 weeks. At 36 weeks, CX11 achieved up to 11.5% weight loss among U.S. obesity patients, with weight loss continuing at a consistent rate and no evidence of a slowing trajectory. Throughout the 36-week double-blind treatment period, CX11 demonstrated a favorable gastrointestinal (GI) tolerability and safety profile. Nausea rates ranged from 33-34%, vomiting from 12-16%, diarrhea from 4-12%, and constipation from 2-12% across different dosing cohorts. The most commonly reported adverse events were GI-related and generally mild to moderate in severity. There were no severe cases of nausea, vomiting, diarrhea, or constipation reported in the study. Gastrointestinal adverse events (GI AEs) primarily occurred during the dose escalation period and gradually subsided during the maintenance period. The overall treatment discontinuation rates due to GI AEs was low, at 5.0%. CX11 continued to demonstrate a favorable hepatic safety pro the study, with no hepatic safety signal observed. To date, more than 1,500 participants have been studied across all CX11 clinical studies, with no hepatic safety signal identified. “We are delighted with these positive U.S. Phase 2 results, which are consistent with the competitive pro in the China Phase 3 program,” said Bo Liang, MD, PhD, Chief Medical Officer of CORXEL. “Together, these datasets reinforce our confidence in CX11 and our conviction to offer patients around the world an effective and highly tolerable option with dosing flexibility. As we look forward to advancing into pivotal global Phase 3 studies for CX11, we are also enthusiastic about the potential of our other cardiometabolic programs in development, including CX12, our internally discovered small molecule amylin RA product.” Cardiometabolic disease remains a leading cause of death, responsible for over 30% of global annual mortality. Medication adherence remains a critical barrier, with studies showing up to 50% of patients with chronic conditions do not take medications as prescribed. Broad adoption of current GLP-1 therapies remains suboptimal due to challenges such as inconvenience of subcutaneous injections, titration difficulty, limited tolerability, and supply constraints. About CX11 CX11 is an investigational oral small molecule GLP-1 receptor agonist designed to address cardiometabolic conditions, including obesity, overweight and type 2 diabetes. With global ex-China rights acquired by CORXEL from Vincentage in December 2024, CX11 aims to overcome limitations of current injectable GLP-1 RAs by offering convenient, once-daily oral administration and weight reduction comparable to injectable GLP-1 RAs. CX11 has demonstrated favorable tolerability, scalability, and accessibility as a small molecule product candidate. Clinical data from Vincentage’s Phase 3 trial in China demonstrated competitive weight loss with a favorable safety and tolerability profile. CORXEL plans to advance CX11 into a global Phase 3 clinical trial. About CORXEL CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world. CORXEL is led by an experienced management team that has a strong track record of identifying, in-licensing and developing attractive clinical product candidates directed at validated targets with proven mechanisms of action (MoAs). CORXEL’s diverse portfolio of clinical-stage product candidates has the potential to redefine treatment standards and address key limitations of current therapies for multiple cardiometabolic indications. CORXEL is developing selective small molecule compounds across the cardiometabolic spectrum with the lead product candidate CX11, an oral small molecule GLP-1 RA under clinical development for obesity and overweight conditions and T2DM, JX10, a thrombolytic and anti-inflammatory agent for acute ischemic stroke and CX12, an oral small molecule amylin RA under pre-clinical development. CORXEL also has additional small molecule programs in development targeting validated obesity targets. For further information about CORXEL, please visit    Media Contact Madelin Hawtin mhawtin@lifescicomms.com

Clinical ResultPhase 2Phase 3

100 Deals associated with Dulaglutide

External Link

KEGG	Wiki	ATC	Drug Bank
D09889	Dulaglutide	A10BJ05	DB09045

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	18 Sep 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoglycemia	Phase 3	Japan	Eli Lilly & Co.	13 Apr 2021
Cardiovascular Diseases	Phase 3	United States	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Argentina	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Australia	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Brazil	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Bulgaria	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Canada	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Chile	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Colombia	Eli Lilly & Co.	22 Jul 2011
Cardiovascular Diseases	Phase 3	Czechia	Eli Lilly & Co.	22 Jul 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04255433 (SURPASS-CVOT \| SURPASS, CTgov)	Phase 3	Diabetes Mellitus, Type 2	13,299	Dulaglutide	xwrwggaoke = dxytbcedsg imdwbfnxmo (vofaixrhwv, kphvotxgib - rwxbcuqmoi) View more	-	08 Jul 2026
ADA2026	Not Applicable	Diabetes Mellitus, Type 2 \| Mild cognitive disorder	1,320	GLP-1 RAs	kpkamsqylf(fbbjunqerb): ARD = -4.9 (95.0% CI, -9.4 to -0.4) View more	Positive	20 Jun 2026
				DPP4i
NCT04255433 (Pubmed \| JAMA Cardiol)	Phase 3	Cardiovascular Diseases \| Diabetes Mellitus, Type 2	13,165	Tirzepatide	azujjfkcte(rexhwpnalp) = hfjyxzdyfq ziwlemnzsd (lpzmgcjtug ) View more	Positive	01 Jun 2026
				Dulaglutide	azujjfkcte(rexhwpnalp) = okmuzhryge ziwlemnzsd (lpzmgcjtug ) View more
ASCO2026	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast HR+/HER2-	1,208	GLP-1 RA+ET+CDK4/6i	-	Positive	29 May 2026
				ET+CDK4/6i alone	jzlhgavjqa(evvatvkoru) = phywupjahm zmtwusxqmn (hbioabjkfg )
DDW2026	Not Applicable	Liver Cirrhosis	119,317	GLP-1 RAs (semaglutide, liraglutide, dulaglutide, tirzepatide)	lgdbthkzao(znsibenzwp): OR = 0.38 (95.0% CI, 0.36 - 0.41) View more	Positive	02 May 2026
				Non-GLP-1 RA users
DDW2026	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	400	GLP-1 RAs	fskpcstdlx(wvzjsqzigy): OR = 0.22 (95.0% CI, 0.12 - 0.39) View more	Positive	02 May 2026
				Non-GLP-1 RAs
AAD2026	Not Applicable	Injection Site Reaction	15,780	Semaglutide	ekiyapmxkq(ajsluzgrmk) = common AEs were rash (26.1%), pruritus (22.1%), alopecia (14.8%), hyperhidrosis (14.6%), and urticaria (3.5%). fijunlhadq (fjywstkxvw )	Positive	27 Mar 2026
				Liraglutide
NCT03204396 (Pubmed \| Eur J Prev Cardiol)	Phase 2	Smoking Cessation	255	Dulaglutide 1.5mg	cmhhttlgvh(qyadapxghx) = systolic blood pressure was stable over the period of 52 weeks after smoking cessation ytsovykjmf (oalpxlricr )	-	10 Oct 2025
NCT05680129 (EECOH-2, Literature) Manual	Phase 3	Diabetes Mellitus, Type 2	621	ecnoglutide 0.6 mg	uvscuteeye(lvjnobmynq) = vjxtquqquk tatoifvmdv (pyyoaiehuy ) View more	Positive	22 Aug 2025
				ecnoglutide 1.2 mg	uvscuteeye(lvjnobmynq) = ipddyeiqyk tatoifvmdv (pyyoaiehuy ) View more
NCT04255433 (SURPASS-CVOT, PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Atherosclerosis	13,299	Mounjaro (tirzepatide)	idfaavsodk(vxgsgvjfvf): HR = 0.92 (95.3% CI, 0.83 - 1.01) Met View more	Non-inferior	31 Jul 2025
				Trulicity (dulaglutide)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis